Little Green Pharma has received another A$2.5m purchase order for its high-THC medicinal cannabis flower medicine from German pharmaceutical wholesaler Demecan.
The purchase is the fourth from Demecan, which has now ordered approximately 47,800 units of LGP medicines at a cost of around $5.7m.
LGP’s existing cultivation facilities are now at full capacity in order to capitalise on growing demand from Germany, Australia and other markets.
In March, the company announced plans to buy properties underlying and adjacent to its current Western Australia facility in order to double its indoor cultivation capacity and, eventually, quadruple production. Construction is expected to start in the second half of 2021.
LGP managing director Fleta Solomon said: “We are currently in a position where all flower product we produce is sold into Australia and overseas markets and we have customers looking for more.
“It heightens the urgency for us to focus on increasing our production capacity to capitalise on the brand equity we have built in the market.”